BR112019005526A2 - agentes antiproliferativos para tratamento de pah - Google Patents

agentes antiproliferativos para tratamento de pah

Info

Publication number
BR112019005526A2
BR112019005526A2 BR112019005526A BR112019005526A BR112019005526A2 BR 112019005526 A2 BR112019005526 A2 BR 112019005526A2 BR 112019005526 A BR112019005526 A BR 112019005526A BR 112019005526 A BR112019005526 A BR 112019005526A BR 112019005526 A2 BR112019005526 A2 BR 112019005526A2
Authority
BR
Brazil
Prior art keywords
antiproliferative agents
treating pah
pulmonary
hypertension
pah
Prior art date
Application number
BR112019005526A
Other languages
English (en)
Inventor
Martin Evans Steven
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112019005526A2 publication Critical patent/BR112019005526A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha

Abstract

hipertensão pulmonar e doenças relacionadas, como hipertensão arterial pulmonar, podem ser tratadas através de administração de uma dose efetiva de um inibidor de cdk, incluindo palbociclib, 6-acetil-8-ciclopentil-5-metil-2-{[5-(piperazin-1-il) piridin-2-il] amino} pirido[2,3-d] pirimidin-7(8h)-ona, ou seu sal farmaceuticamente aceitável.
BR112019005526A 2016-10-20 2017-10-09 agentes antiproliferativos para tratamento de pah BR112019005526A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410566P 2016-10-20 2016-10-20
US201762548629P 2017-08-22 2017-08-22
PCT/IB2017/056226 WO2018073687A1 (en) 2016-10-20 2017-10-09 Anti-proliferative agents for treating pah

Publications (1)

Publication Number Publication Date
BR112019005526A2 true BR112019005526A2 (pt) 2019-06-18

Family

ID=60138667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005526A BR112019005526A2 (pt) 2016-10-20 2017-10-09 agentes antiproliferativos para tratamento de pah

Country Status (15)

Country Link
US (2) US10849903B2 (pt)
EP (2) EP3804724B1 (pt)
JP (2) JP2018076290A (pt)
KR (1) KR20190071763A (pt)
CN (1) CN109843297A (pt)
AU (1) AU2017345367A1 (pt)
BR (1) BR112019005526A2 (pt)
CA (1) CA3040815C (pt)
ES (2) ES2852349T3 (pt)
IL (1) IL266026A (pt)
MX (1) MX2019004602A (pt)
RU (1) RU2019111887A (pt)
SG (1) SG11201902523UA (pt)
TW (1) TWI656876B (pt)
WO (1) WO2018073687A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220003565A (ko) * 2019-04-19 2022-01-10 화이자 인코포레이티드 Pah를 치료하기 위한 항증식제
TWI769382B (zh) * 2019-06-21 2022-07-01 長庚大學 利博西林用於製備治療罹患磷酸二酯酶４介導疾病的患者的醫藥組合物及用途
CN112569357B (zh) * 2019-09-30 2023-03-28 深圳奥萨制药有限公司 双重内皮素受体拮抗剂与利尿剂的组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
EP1280789A1 (en) 2000-05-03 2003-02-05 LG Life Sciences Ltd. Cdk inhibitors having 3-hydroxychromen-4-one structure
PL220952B1 (pl) 2002-01-22 2016-01-29 Warner Lambert Co 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
DE602004017474D1 (de) 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
BRPI0716880A2 (pt) 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
US20090325997A1 (en) * 2006-11-23 2009-12-31 Ergonex Pharma Gmbh Pharmaceutical Compositions For The Treatment Of Capillary Arteriopathy
NZ584454A (en) * 2007-10-12 2011-09-30 Ingenium Pharmaceuticals Gmbh N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases
WO2009121031A1 (en) * 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
WO2010000913A1 (en) 2008-07-04 2010-01-07 Lauri Ilmari Pekansaari Sauna oven center boiler
NZ602832A (en) 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
DK2331547T3 (da) 2008-08-22 2014-11-03 Novartis Ag Pyrrolopyrimidinforbindelser som CDK-inhibitorer
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
WO2011026911A1 (en) 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
MX2012002758A (es) 2009-09-04 2012-04-19 Novartis Ag Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
SG10201508715YA (en) 2010-10-25 2015-11-27 G1 Therapeutics Inc Cdk inhibitors
MX2013005661A (es) 2010-11-19 2013-09-13 Piramal Entpr Ltd Combinacion farmaceutica de paclitaxel y un inhibidor cdk (quinasa dependiente de ciclina).
EP3431475B1 (en) * 2013-02-21 2021-04-07 Pfizer Inc Solid forms of a selective cdk4/6 inhibitor
CR20160471A (es) * 2014-04-11 2016-12-21 Bayer Pharma AG Compuestos novedosos macrocíclicos
WO2016015605A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
WO2016053040A1 (ko) 2014-10-02 2016-04-07 주식회사 엘지화학 리튬 이차 전지용 전해액 첨가제, 상기 전해액 첨가제를 포함하는 비수성 전해액 및 리튬 이차 전지
CN104758292B (zh) * 2015-03-06 2018-05-01 天津医科大学总医院 Pd-0332991在制备防治耐药肿瘤药物的用途
ES2918924T3 (es) * 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta

Also Published As

Publication number Publication date
CA3040815C (en) 2021-07-20
RU2019111887A3 (pt) 2020-11-20
MX2019004602A (es) 2019-06-17
TW201827054A (zh) 2018-08-01
RU2019111887A (ru) 2020-11-20
JP2018076290A (ja) 2018-05-17
IL266026A (en) 2019-06-30
US11439646B2 (en) 2022-09-13
US10849903B2 (en) 2020-12-01
TWI656876B (zh) 2019-04-21
KR20190071763A (ko) 2019-06-24
EP3804724A1 (en) 2021-04-14
JP2021038265A (ja) 2021-03-11
CA3040815A1 (en) 2018-04-26
WO2018073687A1 (en) 2018-04-26
ES2852349T3 (es) 2021-09-13
US20210186974A1 (en) 2021-06-24
AU2017345367A1 (en) 2019-04-04
EP3528812B1 (en) 2020-12-30
SG11201902523UA (en) 2019-05-30
EP3528812A1 (en) 2019-08-28
ES2934846T3 (es) 2023-02-27
US20190240226A1 (en) 2019-08-08
EP3804724B1 (en) 2022-12-07
CN109843297A (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
BR112018007772A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
BR112018000808A2 (pt) compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
BR112018007811A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112019005526A2 (pt) agentes antiproliferativos para tratamento de pah
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CY1122587T1 (el) 1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4η-πυρρολο[3,2-d]πυριμιδιν-4-ονες ως αναστολεις της μυελοϋπεροξειδασης
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
MX2021014575A (es) Derivados heterociclicos condensados.
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
BR112017001695A2 (pt) terapia de combinação
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
WO2016090107A3 (en) Treatment of hepatitis delta virus infection

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements